个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Lin, G.[1] * ; Chu, Q.[2] ; Huang, L.[3] ; Wu, L.[4] ; Yu, Y.[5] ; Liu, Z.[6] ; Huang, D.[7] ;
单位： [1]Fujian Med Univ, Fujian Canc Hosp, Canc Hosp, Fuzhou, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [3]Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China [4]Hunan Canc Hosp, Changsha, Peoples R China [5]Shanghai Chest Hosp, Shanghai, Peoples R China [6]Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China [7]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
出处：
ISSN：

关键词： aumolertinib adenosquamous carcinoma EGFR-TKI

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Fujian Med Univ, Fujian Canc Hosp, Canc Hosp, Fuzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Lin G.,Chu Q.,Huang L.,et al.Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S663-S663.
APA：
Lin, G.,Chu, Q.,Huang, L.,Wu, L.,Yu, Y....&Huang, D..(2023).Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE).JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA：
Lin, G.,et al."Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S663-S663

相关文献

[1]Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial [2]Genomic Origin and EGFR-TKI Efficacy of Pulmonary Adenosquamous Carcinoma [3]Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma [4]Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study [5]Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer [6]EGFR-TKI不良反应管理专家共识 [7]Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results [8]盐酸埃克替尼治疗190例晚期非小细胞肺癌疗效及不良反应 [9]Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials [10]Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases

资源点击量：428 今日访问量：2 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）